New publications are available on our webpage

  • News
  • January 20, 2022

Please check them here.

The last publication was led by Professor Ludovic Pelligand on a prospective clinical trial in normal and critically ill dogs to evaluate the pharmacokinetics (PK) of intravenous amoxicillin combined with clavulanic acid. The authors checked a total of 218 amoxicillin concentrations (AMC) in plasma for healthy and sick dogs and found that the PK of AMC is profoundly different in critically ill dogs compared with normal dogs, with much higher interindividual variability and lower systemic clearance. The study allows to generate hypotheses with regard to higher AMC exposure in clinical dogs and provides supporting data to revise the current AMC clinical breakpoint for IV administration.

Prof. Pelligand is a member of the WG3 in ENOVAT. He is graduated from the École Nationale Vétérinaire d’Alfort (Paris, France) in 2001, where he completed a two-year small animal internal medicine internship. He then completed a 3-year anaesthesia residency at the Royal Veterinary College (RVC), London, UK where he gained his European Diploma of Veterinary Anaesthesia and Anaesthesia in 2006. Then, completed his pharmacology PhD at the RVC in 2010 on the roles of cyclooxygenase (COX) isoenzymes in the regulation of inflammation and the renal function in the cat (supervised by Professor Jonathan Elliott and Professor Peter Lees and Dr. Jon King).

Prof. Pelligand has been back in the clinics as a senior anesthetist since the end of his PhD. He is currently Professor in Veterinary Clinical Pharmacology and Anaesthesia. In addition, he gained the European Diploma in Veterinary Anaesthesia and Analgesia in 2006 and his European Diploma in Veterinary Pharmacology and Toxicology in 2014.

    Leave Your Comment Here